Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Seizures and Neuropsychiatric Toxicity in Patients with Non-Metastatic CRPC Treated with New Antiandrogens: Systematic Review and Meta-Analysis.

< BACK TO ARCHIVE


2021 Mar 18


Oncol Res Treat


http://www.ncbi.nlm.nih.gov/pubmed/33735902?dopt=Abstract

Seizures and Neuropsychiatric Toxicity in Patients with Non-Metastatic CRPC Treated with New Antiandrogens: Systematic Review and Meta-Analysis.

Authors

Seizures and Neuropsychiatric Toxicity in Patients with Non-Metastatic CRPC Treated with New Antiandrogens: Systematic Review and Meta-Analysis.
Sopeña Sutil R, Silva Ruiz J, Garcia Gomez B, Romero-Otero J, Garcia-Gonzalez L, Duarte Ojeda J M, de Velasco G, Castellano Gauna D, Rodriguez Antolin A
Oncol Res Treat. 2021 Mar 18:1-8.
PMID: 33735902.

Abstract

Recently, enzalutamide, apalutamide, and darolutamide have shown benefits in metastasis-free survival in non-metastatic castration-resistant prostate cancer (nmCRPC) patients compared to placebo. Previous evidence about the safety profile of these new androgens is limited. This meta-analysis studies seizure and neuropsychiatric effects of new anti-androgens compared to placebo in nmCRPC patients.
Read This Paper